Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Complement C1 inhibitor protein - Takeda

Drug Profile

Complement C1 inhibitor protein - Takeda

Alternative Names: C1 esterase inhibitor - Baxter Healthcare; C1 esterase inhibitor - Hyland Immuno; C1 esterase inhibitor - Takeda; C1 Inattivatore Umano; C1 inhibitor - Hyland Immuno; C1 inhibitor - Takeda; Complement C1 esterase inhibitor - Baxter Healthcare; Complement C1 esterase inhibitor - Hyland Immuno; Complement C1 esterase inhibitor - Takeda

Latest Information Update: 08 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baxter International
  • Developer Baxalta; Hyland Immuno
  • Class Anti-ischaemics; Antianaemics; Complement C1 inactivator proteins; Eye disorder therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C1r inhibitors; Complement C1s inhibitors; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Angioedema
  • Discontinued Pancreatic disorders; Transplant rejection

Most Recent Events

  • 08 Jan 2019 Shire has been acquired and merged into Takeda
  • 03 Jun 2016 Baxalta has been acquired and merged into Shire
  • 19 Apr 2002 No development reported - Clinical-Phase-Unknown for Angioneurotic oedema in USA (IV-infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top